Idenix plans to use the up-front money to support its hepatitis C virus program, and will focus on its goal of having three major classes of direct-acting HCV antivirals in the clinic in the next 12 months, Ronald C. Renaud, chief financial officer of Idenix, told BioWorld Today
By Catherine Hollingsworth | Bio Perspectives | Tuesday, February 10, 2009
Idenix plans to use the up-front money to support its hepatitis C virus program, and will focus on its goal of having three major classes of direct-acting HCV antivirals in the clinic in the next 12 months, Ronald C. Renaud, chief financial officer of Idenix, told BioWorld Today
By Catherine Hollingsworth | BioWorld Today | Monday, February 9, 2009
Company Executive Base Salary ($000) Bonus ($000) Total ($000) Other ($000) Long-Term Comp. Total Direct Comp. Value Realizable On Exercise Of Options ($000) Value Realized On Vesting Of Restricted Stock ($000) AASTROM BIOSCIENCES Gerald D. Brennan Jr. 212 0 212 0 0 212 0 0 ACADIA PHARMA Thomas H. Aasen 271 49 320 12 163 495 27 0 ACCELRYS Rick E. Russo (1) 273 64 338 3 77 269 0 0 ACCENTIA BIOPHARMA Alan M. Pearce 250 0 250 0 0 250 0 0 ACCESS
Executive Compensation Report | Sunday, March 30, 2008
If studies show that DNase works in bronchitis, study investigator Ronald C. Crystal of the NIH told BioWorld, "there would be a market for it" in that indication as well
Ronald C. Renaud Jr